ADC Therapeutics SA (ADCT) a clinical-stage oncology-focused biotechnology company, reported Thursday that its third-quarter net loss narrowed to $20.33 million or $0.29 per share, from net loss of $31.34 million or $0.62 per share for the same quarter in 2019.
from RTT - Earnings https://ift.tt/3ppjDlS
via IFTTT
No comments:
Post a Comment